MA54845A - Inhibiteurs de ltbp propres à un complexe de tgf-béta et leurs utilisations - Google Patents

Inhibiteurs de ltbp propres à un complexe de tgf-béta et leurs utilisations

Info

Publication number
MA54845A
MA54845A MA054845A MA54845A MA54845A MA 54845 A MA54845 A MA 54845A MA 054845 A MA054845 A MA 054845A MA 54845 A MA54845 A MA 54845A MA 54845 A MA54845 A MA 54845A
Authority
MA
Morocco
Prior art keywords
ltbp
tgf
inhibitors
complex specific
beta complex
Prior art date
Application number
MA054845A
Other languages
English (en)
Inventor
George Coricor
Abhishek Datta
Adam Fogel
Justin W Jackson
Christopher Littlefield
Thomas Schurpf
Stefan Wawersik
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69423073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA54845(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of MA54845A publication Critical patent/MA54845A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA054845A 2019-01-30 2020-01-30 Inhibiteurs de ltbp propres à un complexe de tgf-béta et leurs utilisations MA54845A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962798927P 2019-01-30 2019-01-30

Publications (1)

Publication Number Publication Date
MA54845A true MA54845A (fr) 2021-09-29

Family

ID=69423073

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054845A MA54845A (fr) 2019-01-30 2020-01-30 Inhibiteurs de ltbp propres à un complexe de tgf-béta et leurs utilisations

Country Status (21)

Country Link
US (4) US11214614B2 (fr)
EP (1) EP3689905A3 (fr)
JP (2) JP7724712B2 (fr)
KR (1) KR20210121174A (fr)
CN (1) CN113677711B (fr)
AR (1) AR117918A1 (fr)
AU (1) AU2020216177A1 (fr)
BR (1) BR112021015056A2 (fr)
CA (1) CA3128042A1 (fr)
CL (1) CL2021001993A1 (fr)
CO (1) CO2021010062A2 (fr)
CR (1) CR20210416A (fr)
DO (1) DOP2021000161A (fr)
EA (1) EA202192130A1 (fr)
IL (1) IL285076A (fr)
MA (1) MA54845A (fr)
MX (1) MX2021009175A (fr)
PE (1) PE20220279A1 (fr)
PH (1) PH12021551860A1 (fr)
SG (1) SG11202108099WA (fr)
WO (1) WO2020160291A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211081T1 (hr) 2015-09-15 2021-10-15 Scholar Rock, Inc. Anti-pro/latentna miostatinska protutijela i njihove uporabe
MA49690A (fr) 2017-07-28 2021-05-19 Scholar Rock Inc Inhibiteurs spécifiques du complexe ltbp de tgf-bêta 1 et leurs utilisations
CN113677711B (zh) 2019-01-30 2025-05-30 供石公司 TGFβ的LTBP复合特异性抑制剂及其用途
CN114729370B (zh) 2019-08-28 2025-03-21 中外制药株式会社 跨物种抗潜伏TGF-β1抗体和使用方法
TW202135862A (zh) * 2020-01-11 2021-10-01 美商供石公司 TGFβ抑制劑及其用途
WO2022204581A2 (fr) 2021-03-26 2022-09-29 Scholar Rock, Inc. Inhibiteurs de tgf-bêta et leur utilisation
WO2022256824A1 (fr) * 2021-06-03 2022-12-08 The University Of Chicago Méthodes et compositions pour traiter la fibrose
EP4348260A2 (fr) 2021-06-03 2024-04-10 Scholar Rock, Inc. Inhibiteurs de tgf-bêta et leur utilisation thérapeutique
CA3221555A1 (fr) * 2021-06-23 2022-12-29 Kimberly LONG Inhibiteur de la voie de passage de la myostatine en combinaison avec un activateur de la voie de passage glp-1 pour une utilisation dans le traitement de troubles metaboliques
EP4370148A1 (fr) 2021-07-14 2024-05-22 Scholar Rock, Inc. Inhibiteurs spécifiques du complexe ltbp de tgf bêta1 et leurs utilisations
EP4638496A1 (fr) 2022-12-22 2025-10-29 Scholar Rock, Inc. Anticorps inhibiteurs sélectifs et puissants de l'activation de la myostatine
WO2024187051A1 (fr) 2023-03-07 2024-09-12 Scholar Rock, Inc. Inhibiteurs de tgf-bêta destinés à être utilisés pour traiter un cancer résistant ou réfractaire chez des patients
WO2025240343A1 (fr) 2024-05-13 2025-11-20 Scholar Rock, Inc. Inhibiteurs de tgf-bêta pour le traitement du cancer

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
EP0436597B1 (fr) 1988-09-02 1997-04-02 Protein Engineering Corporation Production et selection de proteines de liaison diversifiees de recombinaison
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2095633C (fr) 1990-12-03 2003-02-04 Lisa J. Garrard Methode d'enrichissement de proteines variantes aux proprietes liantes alterees
EP1820858B1 (fr) 1991-03-01 2009-08-12 Dyax Corporation Protéine chimère comprenant des micro-protéines dotées de deux liaisons disulfure ou plus et ses modes de réalisation
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
US7803553B2 (en) 2003-09-04 2010-09-28 Riken Methods of use of antibodies which recognize a protease cleavage site of an LAP fragment of TGF-β
TR201901929T4 (tr) 2005-02-08 2019-03-21 Genzyme Corp TGFBeta'ya antikorlar.
BRPI0608376A8 (pt) 2005-04-22 2018-10-16 Lilly Co Eli composição de ligação, método de uso de uma composição de ligação, e, kit de detecção
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
WO2011102483A1 (fr) * 2010-02-19 2011-08-25 独立行政法人理化学研究所 ANTICORPS SE LIANT AU TGF-β DU LAP HUMAIN
CN103732623B (zh) * 2011-06-03 2017-09-29 佐马技术有限公司 对TGF‑β具有特异性的抗体
JP2016500704A (ja) 2012-11-06 2016-01-14 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 細胞シグナル伝達を変調するための組成物及び方法
RS61778B1 (sr) * 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
EP3770171A1 (fr) 2015-04-03 2021-01-27 XOMA Technology Ltd. Traitement du cancer à l'aide d'inhibiteurs de tgf-bêta et pd-1
HRP20211081T1 (hr) * 2015-09-15 2021-10-15 Scholar Rock, Inc. Anti-pro/latentna miostatinska protutijela i njihove uporabe
CA3055555A1 (fr) 2016-03-11 2017-09-14 Scholar Rock, Inc. Immunoglobulines se liant a tgfb1 et leur utilisation
NZ789269A (en) 2016-06-13 2026-01-30 Scholar Rock Inc Use of myostatin inhibitors and combination therapies
CN110049773A (zh) 2016-07-14 2019-07-23 供石公司 TGFβ抗体、方法和用途
US10375984B2 (en) 2016-07-18 2019-08-13 R.J. Reynolds Tobacco Company Nonwoven composite smokeless tobacco product
AU2017310027A1 (en) 2016-08-12 2019-01-31 Merck Patent Gmbh Combination therapy for cancer
TW201811827A (zh) * 2016-09-05 2018-04-01 日商中外製藥股份有限公司 抗ＴＧＦ－β１抗體及使用方法
BR112019013908A2 (pt) * 2017-01-06 2020-02-04 Scholar Rock, Inc. inibidores de tgfss1 isoforma-específicos, contexto-permissivos, e seus usos
WO2018129331A1 (fr) 2017-01-07 2018-07-12 Merck Patent Gmbh Schémas posologiques et formes posologiques pour l'inhibition ciblée de tgf-b
EP3571227A1 (fr) 2017-01-20 2019-11-27 Sanofi Anticorps anti-tgf-bêta et leur utilisation
AU2018228435C1 (en) 2017-03-02 2025-09-18 National Research Council Of Canada TGF-beta-receptor ectodomain fusion molecules and uses thereof
MA49690A (fr) * 2017-07-28 2021-05-19 Scholar Rock Inc Inhibiteurs spécifiques du complexe ltbp de tgf-bêta 1 et leurs utilisations
US20210340238A1 (en) 2018-07-11 2021-11-04 Scholar Rock, Inc. TGFß1 INHIBITORS AND USE THEREOF
MA53125A (fr) 2018-07-11 2021-05-19 Scholar Rock Inc Inhibiteurs de tgf?1 sélectifs selon l'isoforme à affinité élevée
CN113677711B (zh) 2019-01-30 2025-05-30 供石公司 TGFβ的LTBP复合特异性抑制剂及其用途

Also Published As

Publication number Publication date
PH12021551860A1 (en) 2022-05-16
US12173059B2 (en) 2024-12-24
BR112021015056A2 (pt) 2022-01-11
KR20210121174A (ko) 2021-10-07
CR20210416A (es) 2021-09-14
CN113677711B (zh) 2025-05-30
IL285076A (en) 2021-09-30
TW202043267A (zh) 2020-12-01
US20250179164A1 (en) 2025-06-05
CN113677711A (zh) 2021-11-19
AR117918A1 (es) 2021-09-01
CL2021001993A1 (es) 2022-04-08
US11365245B2 (en) 2022-06-21
US20220064276A1 (en) 2022-03-03
CO2021010062A2 (es) 2021-08-09
WO2020160291A3 (fr) 2020-09-10
WO2020160291A9 (fr) 2020-10-15
WO2020160291A2 (fr) 2020-08-06
JP2022524281A (ja) 2022-05-02
JP2025172758A (ja) 2025-11-26
US20220363741A1 (en) 2022-11-17
AU2020216177A1 (en) 2021-09-23
EP3689905A3 (fr) 2021-02-24
EA202192130A1 (ru) 2021-12-28
EP3689905A2 (fr) 2020-08-05
PE20220279A1 (es) 2022-02-25
DOP2021000161A (es) 2021-09-15
US11214614B2 (en) 2022-01-04
US20210047396A1 (en) 2021-02-18
CA3128042A1 (fr) 2020-08-06
MX2021009175A (es) 2021-09-14
SG11202108099WA (en) 2021-08-30
JP7724712B2 (ja) 2025-08-18

Similar Documents

Publication Publication Date Title
MA54845A (fr) Inhibiteurs de ltbp propres à un complexe de tgf-béta et leurs utilisations
MA49690A (fr) Inhibiteurs spécifiques du complexe ltbp de tgf-bêta 1 et leurs utilisations
EP3870579A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
MA55627A (fr) Agonistes de glp-1r et leurs utilisations
EP3866789A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
EP3600273A4 (fr) Inhibiteurs de cd73 et leurs utilisations
EP3886843A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
EP3768664A4 (fr) Inhibiteurs de shp2 et leurs utilisations
EP3529279A4 (fr) Agents de liaison à cd133 et leurs utilisations
EP3389658A4 (fr) Inhibiteurs de glycosidase et leurs utilisations
EP3938369A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
EP3761992A4 (fr) Inhibiteurs d'arginase
EP3303379A4 (fr) Agents de liaison à tigit et leurs utilisations
EP3914357A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
EP3341007A4 (fr) Inhibiteurs de malt1 et leurs utilisations
EP3870162A4 (fr) Inhibiteurs de ssao et leurs utilisations
EP3976009A4 (fr) Inhibiteurs de bax et leurs utilisations
EP3908522A4 (fr) Dispositif de test de charge de couple
EP3947387A4 (fr) Inhibiteurs de prmt5 et leurs utilisations
EP4103564A4 (fr) Modulateurs de p2x3
EP3327053A4 (fr) Copolymère à bloc (méth)acrylique
EP4459437A4 (fr) Dispositif d'entrée
EP3966201A4 (fr) Thiosemicarbazates et leurs utilisations
EP4083759C0 (fr) Dispositif d'entrée
JP1705516S (ja) サーキュレーター